

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT						
NATURE OF CONVEYANCE:	ASSIGNMENT						
CONVEYING PARTY DATA							
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Yuanxi ZHOU</td> <td>06/27/2011</td> </tr> <tr> <td>Yongbao ZHU</td> <td>06/29/2011</td> </tr> </tbody> </table>		Name	Execution Date	Yuanxi ZHOU	06/27/2011	Yongbao ZHU	06/29/2011
Name	Execution Date						
Yuanxi ZHOU	06/27/2011						
Yongbao ZHU	06/29/2011						
RECEIVING PARTY DATA							
Name:	Alectos Therapeutics Inc.						
Street Address:	8999 Nelson Way						
City:	Burnaby, British Columbia						
State/Country:	CANADA						
Postal Code:	V5A 4B5						
PROPERTY NUMBERS Total: 1							
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13697179</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13697179		
Property Type	Number						
Application Number:	13697179						
CORRESPONDENCE DATA							
Fax Number:	6174287045						
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>							
Phone:	6174280200						
Email:	patentadministrator@clarkelbing.com						
Correspondent Name:	Michael J. Belliveau, Ph.D.						
Address Line 1:	Clark & Elbing LLP						
Address Line 2:	101 Federal Street						
Address Line 4:	Boston, MASSACHUSETTS 02110						
ATTORNEY DOCKET NUMBER:	50842-008001						
NAME OF SUBMITTER:	Michael J. Belliveau, Ph.D.						
<p>Total Attachments: 3 source=50842_008001_Assignment_Zhou#page1.tif source=50842_008001_Assignment_Zhou#page2.tif source=50842_008001_Assignment_Zhou#page3.tif</p>							

CH \$40.00 13697179

ASSIGNMENT

WHEREAS, We:

Yuanxi ZHOU, whose full post office address is 8999 Nelson Way, Burnaby, British Columbia, V5A 4B5, Canada

Yongbao ZHU, whose full post office address is 8999 Nelson Way, Burnaby, British Columbia, V5A 4B5, Canada

(hereinafter the "ASSIGNORS"),

are the joint inventors of the invention or inventions entitled SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF (hereinafter the "Invention"), filed as a PCT International Patent Application under the Patent Cooperation Treaty on May 10, 2011 under Application No. PCT/CA2011/000548, and claiming priority to US Application No. 61/333,686, filed May 11, 2010 and US Application No. 61/426,569, filed December 23, 2010;

WHEREAS, ALECTOS THERAPEUTICS INC. (hereinafter referred to as "ASSIGNEE") having a place of business at 8999 Nelson Way, Burnaby, BC V5A 4B5, Canada is desirous of acquiring and having assigned to it the full right, title and interest of the undersigned inventors in and to the Invention and in and to any Letters Patent that may be granted therefor in any and all countries and jurisdictions; and

WHEREAS WE have agreed to make such assignment;

NOW, THEREFORE, in consideration of the foregoing premises, and of the sum of one dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, WE, hereby sell, assign and transfer absolutely to the ASSIGNEE our full and exclusive right, title and interest in and to: (a) the Invention worldwide; (b) any and all patent applications for the Invention in all countries and jurisdictions and under all conventions and treaties, including the right to claim for any and all applications any priority rights to which such applications are entitled under conventions, treaties or otherwise, and all

divisions, extensions, continuations, continuations-in-part, provisionals, non-provisionals, substitutions and renewals thereof; (c) all Letters Patent which may be granted therefor in any and all countries and jurisdictions, and any renewals, reissues, re-examinations or extensions of the Letters Patent, and (d) the exclusive right to bring or participate in any proceeding for past infringement or any other actionable right under all of the foregoing and to receive all remedies that arise therefrom, to the end of the term for which the Letters Patent may be granted, as fully and entirely as the same would have been held by us had this Assignment not been made.

WE represent that, other than by way of this Assignment, WE have not assigned, licensed or otherwise encumbered any right, title or interest in or to the Invention.

In addition, WE hereby authorize and request the patent offices in all countries and jurisdictions to issue any and all of the Letters Patent, when granted, to the ASSIGNEE.


Further, WE agree that WE will communicate to the ASSIGNEE or its representatives any facts known to us respecting the Invention, and testify in any legal proceeding, sign all lawful papers, execute all papers relating to all patent applications including all divisionals, continuations, continuations-in-part, extensions, renewals, provisionals, non-provisionals or substitutes thereof, and the Letters Patent including any renewal, re-examination, extension and reissue thereof, execute all necessary assignment papers to cause any and all of the Letters Patent to be issued to the ASSIGNEE, make all rightful oaths, and, generally do everything possible to aid the ASSIGNEE, its successors and assigns, to obtain and enforce proper protection for the Invention in any and all countries and jurisdictions.

The undersigned hereby authorizes the firm of Gowling Lafleur Henderson LLP to correct errors in this assignment or to insert any further identification or other information necessary or desirable to make this Assignment suitable for recordal in any country.


EXECUTED at Burma by, this 27
day of 27 June, 2011.

Witness:

Inventor:



Print Name: JIANYU SUN




Yuanxi ZHOU


EXECUTED at Burma by, this 29
day of June, 2011.

Witness:

Inventor:



Print Name: JIANYU SUN



Yongbao ZHU